Valifenalate
Based on 1 Customer Validation
Valifenalate (IR5885; Valiphenal) is an insecticide agent and fungicide, which is approved for application on high-value crops such as grapes, tomatoes and other vegetables. Valifenalate interferes with cell-wall synthesisValifenalate is effective against various types of mildew. Valifenalate can be used against crown rot of rose cuased by Phytophthora citrophthora. Valifenalate induces non-adverse thyroid changes via adaptive induction of uridine 5’-diphosphoglucuronosyltransferase (UGT) in the liver of dogs and rats.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.09%
- No. CAS: 283159-90-0
- Fòrmula: C19H27ClN2O5
- Peso molecular:398.88
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
Valifenalate (100-300 μM) induces UGT2B31 mRNA expression with the maximal effect observed at the highest concentration and the expression levels being the highest on day 6, whilst increasing UGT1A6 mRNA expression by approximately 2-fold in dog hepatocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Valifenalate (50-750 mg/kg, p.o., 13 w) increases the body weight adjusted thyroid/parathyroid weights in male dogs[3].
Valifenalate (50-250 mg/kg, p.o., 52 w) results in minimal or slight follicular cell hypertrophy in Beagle dogs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Han Wistar rat model with chronic toxicity/carcionogenicity[3]
-
Dosage:0, 15, 150, 1000 mg/kg/day
-
Administration:Oral gavage (p.o.) for 52 w
-
Result:Lowered mean body weight gains in male rate at 150 and 1000 mg/kg.
Resulted in an increase in the incidence of follicular cell hypertrophy in the thyroids occurred only at the highest dose of 1000 mg/kg, only in male during week 52.
Chemical Information
-
No. CAS 283159-90-0
-
Appearance Solid
-
Peso molecular 398.88
-
Fòrmula C19H27ClN2O5
-
Color White to off-white
-
SMILES
O=C([C@H](C(C)C)NC(OC(C)C)=O)NC(C1=CC=C(Cl)C=C1)CC(OC)=O
-
Synonyms
IR5885; Valiphenal
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Solvente y solubilidad
In Vitro:
DMSO : ≥ 41 mg/mL (102.79 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Pureza y Documentación
-
Ficha de datos (291 KB)
-
SDS (562 KB)
- English - EN (562 KB)
- Français - FR (562 KB)
- Deutsch - DE (562 KB)
- Norwegian - NO (562 KB)
- Español - ES (562 KB)
- Swedish - SV (562 KB)
- Italian - IT (562 KB)
- Korean - KR (562 KB)
- Portuguese - PT (562 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5070 mL | 12.5351 mL | 25.0702 mL | 62.6755 mL |
| 5 mM | 0.5014 mL | 2.5070 mL | 5.0140 mL | 12.5351 mL | |
| 10 mM | 0.2507 mL | 1.2535 mL | 2.5070 mL | 6.2675 mL | |
| 15 mM | 0.1671 mL | 0.8357 mL | 1.6713 mL | 4.1784 mL | |
| 20 mM | 0.1254 mL | 0.6268 mL | 1.2535 mL | 3.1338 mL | |
| 25 mM | 0.1003 mL | 0.5014 mL | 1.0028 mL | 2.5070 mL | |
| 30 mM | 0.0836 mL | 0.4178 mL | 0.8357 mL | 2.0892 mL | |
| 40 mM | 0.0627 mL | 0.3134 mL | 0.6268 mL | 1.5669 mL | |
| 50 mM | 0.0501 mL | 0.2507 mL | 0.5014 mL | 1.2535 mL | |
| 60 mM | 0.0418 mL | 0.2089 mL | 0.4178 mL | 1.0446 mL | |
| 80 mM | 0.0313 mL | 0.1567 mL | 0.3134 mL | 0.7834 mL | |
| 100 mM | 0.0251 mL | 0.1254 mL | 0.2507 mL | 0.6268 mL |
Valifenalate Related Classifications
HY-17518 Related Classifications
Powered by Bioz